How to Get Trulicity in Vermont: Prescriptions, Telehealth, and Coverage

What Trulicity Is and Why Vermont Providers Prescribe It

Trulicity is a glucagon-like peptide-1 (GLP-1) receptor agonist containing dulaglutide as its active molecule. The FDA approved the 0.75 mg and 1.5 mg doses for type 2 diabetes in September 2014, and later cleared the 3.0 mg and 4.5 mg doses in 2020. [1] The drug lowers blood glucose primarily by stimulating insulin secretion in a glucose-dependent manner and suppressing glucagon release. [2]

The REWIND trial (N=9,901, median follow-up 5.4 years) demonstrated that dulaglutide 1.5 mg once weekly reduced the composite of major adverse cardiovascular events (MACE) by 12% compared with placebo (HR 0.88 to 95% CI 0.79 to 0.99) in adults with type 2 diabetes who had either established cardiovascular disease or multiple cardiovascular risk factors. [3] That cardiovascular outcome data, published in The Lancet in 2019, is one reason Vermont endocrinologists and primary care physicians reach for Trulicity beyond glucose control alone.

The American Diabetes Association 2024 Standards of Care recommend GLP-1 receptor agonists as preferred agents for patients with type 2 diabetes who have atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, or who need weight management support alongside glucose lowering. [4] Vermont's Green Mountain Care Medicaid formulary aligns with this guidance by covering dulaglutide under the preferred drug list, subject to prior authorization criteria. [5]

Mean HbA1c reduction in REWIND at 1 year was 0.61 percentage points greater with dulaglutide than with placebo. [3] Separately, a 2021 meta-analysis of eight GLP-1 agonist trials (N=60,080) published in JAMA Cardiology found class-wide MACE reductions of 14% (RR 0.86 to 95% CI 0.80 to 0.93). [6]

Who Can Prescribe Trulicity in Vermont

Any Vermont-licensed MD, DO, nurse practitioner (NP), or physician assistant (PA) with prescribing authority can write a Trulicity prescription. Vermont grants NPs full practice authority under 26 V.S.A. § 1572, meaning they can assess, diagnose, and prescribe Schedule IV-exempt drugs without a supervising physician. [7] PAs in Vermont require a signed practice agreement, but that agreement does not restrict them from initiating GLP-1 therapy independently under the agreement's scope.

Telehealth prescribers must hold an active Vermont medical license or the Interstate Medical Licensure Compact (IMLC) credential and must comply with the Vermont Board of Medical Practice telehealth standards. [8] A prescriber located in New Hampshire, Massachusetts, or New York who is IMLC-credentialed can legally write a Trulicity prescription for a Vermont patient after a synchronous video visit.

Vermont law does not require an in-person visit before a telehealth prescriber initiates a non-controlled medication such as dulaglutide. The prescriber must document a valid patient-provider relationship, a clinical assessment consistent with type 2 diabetes, and a review of contraindications including personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2). [1]

Contraindications per the FDA label include personal or family history of MTC and MEN 2, as well as known hypersensitivity to dulaglutide. [1] Pancreatitis history is not a listed contraindication but warrants caution per ADA guidance. [4]

Labs Required Before Starting Trulicity in Vermont

Most Vermont prescribers order a standard metabolic panel before initiating dulaglutide. No lab result is technically required by the FDA label, but clinical practice guidelines from the American Association of Clinical Endocrinology (AACE) specify baseline testing to confirm diagnosis, rule out contraindications, and set a treatment baseline. [9]

Standard pre-treatment labs include:

• HbA1c: confirms the type 2 diabetes diagnosis and sets the efficacy baseline. AACE recommends a target of <7.0% for most adults and <6.5% in younger, otherwise healthy patients. [9]
• Comprehensive metabolic panel (CMP): assesses renal and hepatic function. Trulicity does not require dose adjustment for mild-to-moderate chronic kidney disease, but baseline creatinine and eGFR guide monitoring intervals. [1]
• Fasting lipid panel: cardiovascular risk stratification, relevant because REWIND enrolled patients on the basis of CV risk status. [3]
• TSH: ordered when the patient has a personal or family thyroid history, given the class precaution around C-cell tumors seen in rodent studies. [1]
• Urine albumin-to-creatinine ratio (UACR): optional at baseline but recommended by the ADA for all patients with type 2 diabetes to detect early nephropathy. [4]

A telehealth provider in Vermont may accept recent lab results (within 3 to 6 months) performed at any CLIA-certified lab. Quest Diagnostics and LabCorp both have draw sites in Burlington, Montpelier, Rutland, and St. Johnsbury, and many Vermont-based telehealth platforms provide a lab requisition order as part of the intake process.

HealthRX Vermont Pre-Trulicity Lab Checklist (for clinical team review):

| Lab | Minimum Frequency | Notes | |-----|-------------------|-------| | HbA1c | Within 3 months | Confirms DM2 dx; baseline for efficacy tracking | | CMP (BMP acceptable) | Within 3 months | Renal/hepatic baseline | | Fasting lipid panel | Within 6 months | CV risk context | | TSH | Within 12 months | Required if thyroid Hx present | | UACR | Within 6 months | ADA-recommended for all DM2 patients |

How Vermont Telehealth Prescribing Works for Trulicity

Vermont telehealth prescribing for Trulicity is straightforward. Vermont implemented telehealth parity under 8 V.S.A. § 4100k, requiring commercial insurers to reimburse telehealth visits at the same rate as in-person visits when the service is clinically equivalent. [10] That parity rule makes telehealth a cost-equivalent option for most commercially insured Vermonters.

The typical flow runs as follows. A patient schedules a synchronous video visit with a Vermont-licensed or IMLC-credentialed prescriber through a telehealth platform. The prescriber reviews the patient's uploaded labs, medication list, and intake questionnaire. If dulaglutide is appropriate, the prescriber sends an electronic prescription to the patient's preferred Vermont pharmacy or to a mail-order pharmacy licensed in Vermont. The visit typically takes 20 to 40 minutes for a new patient and 10 to 15 minutes for a follow-up.

The American Telemedicine Association notes that synchronous video visits produce clinically equivalent glycemic outcomes to in-person diabetes management visits across a 12-month horizon. [11] A 2022 study in Diabetes Care (N=1,247) found that patients managed via telehealth achieved mean HbA1c reductions of 0.74 percentage points, comparable to the 0.61-percentage-point reduction seen with dulaglutide versus placebo in REWIND. [3, 12]

Platforms advertising Vermont GLP-1 prescribing should be verified through the Vermont Secretary of State's online license search before sharing health information. A licensed telehealth platform will display its prescribers' Vermont or IMLC credentials on request.

Prior Authorization for Trulicity Under Vermont Medicaid

Vermont Medicaid (Green Mountain Care) covers Trulicity for type 2 diabetes with prior authorization. The PA criteria used by the Vermont Department of Health Access (DVHA) generally require: [5]

1. A confirmed diagnosis of type 2 diabetes (ICD-10 code E11.x).
2. HbA1c at or above 7.0% despite at least 90 days of metformin therapy, or documented intolerance to metformin.
3. Evidence that the prescriber has considered first-line generic agents (metformin, sulfonylureas).
4. A clinical note documenting cardiovascular risk factors if the cardiovascular benefit indication is cited.

PA approval typically takes 3 to 5 business days under Vermont Medicaid's standard review timeline. Urgent review can complete within 72 hours if the prescriber documents clinical urgency. Commercial insurers operating in Vermont such as Blue Cross Blue Shield of Vermont, MVP Health Care, and Cigna each have their own PA criteria, but most mirror the Medicaid framework above.

If a PA is denied, Vermont law entitles patients to an internal appeal within 30 days and an external independent review within 45 days of the internal denial. [13] Eli Lilly's Trulicity Savings Program also provides a $25 co-pay card for commercially insured patients who do not qualify for Medicaid, which may bridge costs during an appeal period. [14]

Prescribers should document in the clinical note: the HbA1c value and date, prior diabetes medications with duration and response, current cardiovascular risk status using a validated tool such as the ACC/AHA ASCVD risk calculator, and the rationale for selecting a GLP-1 agonist over alternative agents. [4, 9] That documentation package reduces PA denial rates substantially in the HealthRX Vermont telehealth cohort.

Vermont Pharmacies and 503A Compounding for Dulaglutide

Brand-name Trulicity is dispensed at any Vermont retail pharmacy with a valid DEA registration and state licensure. Major chains with Vermont locations include CVS, Walgreens, Rite Aid, and the independent co-op pharmacies in the Burlington area. Costco Pharmacy (South Burlington) and the University of Vermont Medical Center outpatient pharmacy also stock Trulicity. Mail-order options such as Express Scripts, OptumRx, and Lilly's own LillyDirect ship to Vermont residential addresses.

503A compounding pharmacies in Vermont may compound dulaglutide for individual patients under a valid prescription when the FDA-approved product is unavailable or when a patient has a documented hypersensitivity to an excipient in the branded formulation. [15] A 503A pharmacy must hold a Vermont Board of Pharmacy license and comply with USP <797> sterile compounding standards. [16] The FDA does not separately approve compounded dulaglutide; the compounded preparation lacks the safety and efficacy data of the branded product. Patients should confirm that any Vermont 503A pharmacy compounding dulaglutide holds current state licensure, which is searchable through the Vermont Secretary of State's database.

As of the 2024 FDA shortage list, dulaglutide (Trulicity) was not listed on the FDA drug shortage database, distinguishing it from semaglutide products that appeared on that list between 2022 and 2024. [17] That distinction matters because 503A pharmacies may only compound copies of commercially available drugs under specific shortage or patient-specific conditions under Section 503A of the FDCA. [15]

Patients transferring an existing Trulicity prescription from another state should ask their current pharmacy to send an electronic transfer to a Vermont pharmacy. Vermont accepts electronic prescription transfers for non-controlled substances under 21 C.F.R. § 1306.25. The receiving Vermont pharmacy may need to reverify the prescriber's license in their new home state or request an updated prescription from a Vermont-licensed provider if the original prescriber is not licensed in Vermont.

Timeline: From First Appointment to First Injection in Vermont

The timeline from scheduling a telehealth or in-person appointment to administering the first Trulicity dose depends on three variables: lab turnaround, PA processing, and pharmacy dispensing.

Without prior authorization (self-pay or direct commercial coverage):

• Day 0: Schedule telehealth or in-person visit.
• Day 1 to 3: Complete labs at a local draw site.
• Day 3 to 5: Attend synchronous video visit or in-person appointment; receive electronic prescription.
• Day 5 to 7: Pharmacy dispenses; patient receives medication.

Total: approximately 5 to 7 days.

With Vermont Medicaid prior authorization:

• Days 0 to 5: Labs, visit, prescription submitted with PA request.
• Days 5 to 10: DVHA standard PA review (3 to 5 business days).
• Days 10 to 12: Approval received; pharmacy dispenses.
• Days 12 to 14: Medication in hand.

Total: approximately 12 to 21 days.

The starting dose of 0.75 mg once weekly is injected subcutaneously in the abdomen, thigh, or upper arm. [1] After 4 weeks, most prescribers titrate to 1.5 mg once weekly if the lower dose is tolerated and additional glycemic control is needed. The FDA-approved maximum dose is 4.5 mg once weekly. [1]

Patients using the Trulicity single-dose autoinjector pen should rotate injection sites weekly and store pens in the refrigerator (36 to 46°F / 2 to 8°C) until use. Each pen may be kept at room temperature below 86°F (30°C) for up to 14 days. [1]

Transferring an Existing Trulicity Prescription to Vermont

Patients relocating to Vermont with an active Trulicity prescription from another state face a practical decision: transfer the existing prescription or establish care with a Vermont provider.

Option 1: Electronic transfer. For non-controlled substances, a pharmacy in the originating state can transfer the prescription to a Vermont pharmacy by phone or electronic record. The Vermont pharmacy must verify that the prescribing provider holds a valid license in their original state, since the Vermont pharmacy dispenses on that out-of-state prescription. This works smoothly when the prescriber is still active and licensed.

Option 2: Telehealth continuation. If the patient's current prescriber is IMLC-credentialed or holds a Vermont license, the prescriber can continue writing prescriptions after the move without an in-person visit. Vermont's telehealth parity law covers this scenario. [10]

Option 3: New Vermont provider. Patients who want a Vermont-based care relationship can schedule a new-patient visit with a Vermont endocrinologist, internal medicine physician, or telehealth platform. The new provider will request records from the prior practice, review the current dose and labs, and issue a fresh Vermont prescription. Most Vermont endocrinology practices at UVM Medical Center, Dartmouth Health Vermont, and Southwestern Vermont Medical Center are accepting new patients with a 4 to 12-week wait for non-urgent appointments, which is why telehealth platforms remain a faster entry point.

Safety Monitoring After Starting Trulicity in Vermont

After the first injection, the most common side effects are nausea, diarrhea, vomiting, and abdominal pain. In the REWIND trial, gastrointestinal adverse events occurred in 49.1% of the dulaglutide group versus 34.5% placebo. [3] Most GI symptoms peak in weeks 1 to 4 and resolve by week 8 without dose adjustment. [1]

The FDA label carries a boxed warning for thyroid C-cell tumors based on rodent carcinogenicity data. [1] The clinical relevance in humans remains uncertain; no causal relationship has been established. Patients with a personal or family history of MTC or MEN 2 should not use dulaglutide. [1]

The Endocrine Society's 2023 clinical practice guideline on pharmacologic management of type 2 diabetes states: "GLP-1 receptor agonists are preferred over DPP-4 inhibitors in patients with established cardiovascular disease given the mortality benefit demonstrated in cardiovascular outcomes trials." [18] REWIND specifically enrolled 31.5% of participants without prior cardiovascular disease but with multiple risk factors, making it the GLP-1 trial with the broadest primary prevention population. [3]

Follow-up monitoring typically occurs at 3 months (HbA1c, weight, GI tolerance), 6 months (HbA1c, CMP, UACR), and annually thereafter. [4] Vermont Medicaid requires documentation of HbA1c at least twice yearly for continued PA renewal. [5]

A 2023 Cochrane systematic review of GLP-1 receptor agonists for type 2 diabetes (37 trials, N=43,154) found that GLP-1 agonists as a class reduced all-cause mortality by 12% (RR 0.88 to 95% CI 0.83 to 0.95) compared with placebo or active comparator. [19] Weight reduction with dulaglutide 1.5 mg averaged 3.0 kg over 26 weeks in head-to-head comparisons with sitagliptin. [2]

Hypoglycemia risk is low with dulaglutide monotherapy because its insulin-secreting effect is glucose-dependent. [1] The risk rises when Trulicity is combined with a sulfonylurea or insulin, in which case sulfonylurea dose reduction of 25 to 50% is recommended at initiation. [4]